|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2006
Low-dose inhaled and nasal corticosteroid use and the risk of cataracts
1 Division of Clinical Epidemiology, and 5 Dept of Ophthalmology, Royal Victoria Hospital, and 2 Division of Respiratory Medicine, McGill University Health Center, and 3 Dept of Epidemiology and Biostatistics and of Medicine, McGill University, and 4 Dept of Respiratory Medicine, Mount Sinai Hospital and Respiratory Medicine Service, Fleury Hospital Centre, Montreal, QC, Canada.
CORRESPONDENCE: P. Ernst, Division of Clinical Epidemiology, Royal Victoria Hospital, 687 Pine Avenue West, Ross 4.29, Montreal, Québec H3A 1A1, Canada. Fax: 1 5148431493. E-mail: Pierre.ernst{at}clinepi.mcgill.ca
Keywords: Asthma, cataracts, chronic obstructive pulmonary disease, elderly, inhaled corticosteroids, nasal corticosteroids
Received: April 11, 2005
Accepted January 20, 2006
Orally inhaled corticosteroid use has been convincingly linked to an increase in the risk of cataracts, although the risk at lower doses in common use remains uncertain. The potential risk of cataracts with the use of nasal corticosteroids is unknown.
A matched nested case–control analysis was performed in a population-based cohort of elderly people who had been dispensed medications for airway disease, as identified through a universal drug benefit plan.
Inhaled corticosteroid use was associated with a dose-related increase in both the risk of all cataracts and severe cataracts requiring extraction, and the increase in risk of severe cataracts was apparent even at daily doses of
It is concluded that, among the elderly, even low doses of inhaled corticosteroids are associated with a small but significant excess risk of cataracts requiring extraction. Such an excess risk was not observed with nasal corticosteroids.
500 µg. An excess risk with nasal corticosteroids was not apparent for severe cataracts.
This article has been cited by other articles:
|
|
 |
|
  S. Suissa and P. J. Barnes Inhaled corticosteroids in COPD: the case against Eur. Respir. J., July 1, 2009; 34(1): 13 - 16. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Singh, A. V. Amin, and Y. K. Loke Long-term Use of Inhaled Corticosteroids and the Risk of Pneumonia in Chronic Obstructive Pulmonary Disease: A Meta-analysis Arch Intern Med, February 9, 2009; 169(3): 219 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Mannino, D. Thorn, A. Swensen, and F. Holguin Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD Eur. Respir. J., October 1, 2008; 32(4): 962 - 969. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Suissa Medications to Modify Lung Function Decline in Chronic Obstructive Pulmonary Disease: Some Hopeful Signs Am. J. Respir. Crit. Care Med., August 15, 2008; 178(4): 322 - 323. [Full Text] [PDF]
|
|
|
|
|
|
E. D. Bateman, S. S. Hurd, P. J. Barnes, J. Bousquet, J. M. Drazen, M. FitzGerald, P. Gibson, K. Ohta, P. O'Byrne, S. E. Pedersen, et al. Global strategy for asthma management and prevention: GINA executive summary Eur. Respir. J., January 1, 2008; 31(1): 143 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ernst, A. V. Gonzalez, P. Brassard, and S. Suissa Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease and the Risk of Hospitalization for Pneumonia Am. J. Respir. Crit. Care Med., July 15, 2007; 176(2): 162 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ernst, A. McIvor, F. M. Ducharme, L.-P. Boulet, M. FitzGerald, K. R. Chapman, T. Bai, and for the Canadian Asthma Guideline Group Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med, November 7, 2006; 145(9): 692 - 694. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |